Hasan Karanlik1, Hatice Odabas2, Ilknur Yildirim3, Ilker Ozgur4, Berkay Kilic4, Fatma Sen2, Sidika Kurul3, Adnan Aydiner2. 1. Surgical Oncology Unit, Institute of Oncology, Istanbul University, Capa, Istanbul, Turkey. hasankaranlik@yahoo.com. 2. Division of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey. 3. Surgical Oncology Unit, Institute of Oncology, Istanbul University, Capa, Istanbul, Turkey. 4. Department of Surgery, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
Abstract
BACKGROUND: Our aim was to evaluate whether it is safe to use a totally implantable venous access device (TIVAD) on the day of implantation. METHODS: We investigated data from 1315 cancer patients divided into two groups according to the time interval between TIVAD placement and the first use of the TIVAD to adminster chemotherapy: patients whose devices were used during the first 24 h after placement were enrolled into group 1 and patients whose devices were first used more than 24 h after device placement were enrolled into group 2. RESULTS: Early complications were all related to device insertion and occurred before chemotherapy administration. Infection and venous thrombosis were the most frequent complications during the first 6 months after TIVAD insertion in both groups. However, the frequency of late complications was statistically the same for the two groups. CONCLUSIONS: The early use of TIVADs appears safe. Usage of the catheter for chemotherapy administration during the first 24 h after insertion has no effect on the rate of complications.
BACKGROUND: Our aim was to evaluate whether it is safe to use a totally implantable venous access device (TIVAD) on the day of implantation. METHODS: We investigated data from 1315 cancerpatients divided into two groups according to the time interval between TIVAD placement and the first use of the TIVAD to adminster chemotherapy: patients whose devices were used during the first 24 h after placement were enrolled into group 1 and patients whose devices were first used more than 24 h after device placement were enrolled into group 2. RESULTS: Early complications were all related to device insertion and occurred before chemotherapy administration. Infection and venous thrombosis were the most frequent complications during the first 6 months after TIVAD insertion in both groups. However, the frequency of late complications was statistically the same for the two groups. CONCLUSIONS: The early use of TIVADs appears safe. Usage of the catheter for chemotherapy administration during the first 24 h after insertion has no effect on the rate of complications.
Entities:
Keywords:
Catheter; First use; Totally implantable venous access device
Authors: F Narducci; M Jean-Laurent; L Boulanger; S El Bédoui; Y Mallet; J L Houpeau; A Hamdani; N Penel; C Fournier Journal: Eur J Surg Oncol Date: 2011-08-09 Impact factor: 4.424
Authors: Jo Caers; Christel Fontaine; Vincent Vinh-Hung; Johan De Mey; Gerrit Ponnet; Chris Oost; Jan Lamote; Jacques De Greve; Benjamin Van Camp; Patrick Lacor Journal: Support Care Cancer Date: 2004-11-05 Impact factor: 3.603
Authors: J Vardy; K Engelhardt; K Cox; J Jacquet; A McDade; M Boyer; P Beale; M Stockler; R Loneragan; B Dennien; R Waugh; S J Clarke Journal: Br J Cancer Date: 2004-09-13 Impact factor: 7.640